Last updated: 2026-10-14 20:07:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Insmed, Inc. (INSM) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $97.79, with a market capitalization of $21.52B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $90.39 to $212.75. This page covers its latest market performance, valuation, price trends and company information.
$21.52B | |
$97.39 | |
$212.75 | |
$2.64 | |
$96.79 | |
2.44M | |
2.59M | |
-- | |
$212.75 | |
$90.39 | |
-- | |
-- |
Insmed, Inc. (INSM) is trading at $97.83 in after-hours trading as of 2026-10-14 19:50:40, up 1.07% ($1.04) from the regular-session close of $96.79.
After-hours trading shows how investors are pricing INSM after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Insmed, Inc. (INSM) moved from $103.83 to $97.79, representing a decline of 5.81% ($6.04).
The stock traded between $95.96 and $108.75 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 3.40 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 6.1%
INSM is currently trading at $97.79, placing it 6.1% of the way from its 52-week low of $90.39 to its 52-week high of $212.75. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 1664 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Insmed, Inc. (INSM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.